Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Fulcrum Therapeutics is undertaking a major restructuring after discontinuing development of pociredir for sickle cell disease. The board approved a plan that cuts the workforce by about 85%, reducing headcount from 57 to 9 full-time employees, with the changes expected to be largely complete in the second quarter of 2026.

The company expects approximately $4.2 million in charges tied mainly to severance, benefits and related costs, most of which will require future cash payments during the same quarter. Fulcrum is also conducting a broad review of strategic alternatives and has hired Leerink Partners LLC to advise on potential transactions such as mergers, acquisitions, or asset sales, though there is no assurance that any deal will occur.

Positive

None.

Negative

Severe downsizing of operations: Fulcrum is reducing its workforce by approximately 85%, from 57 to 9 employees, signaling a major contraction of its operating footprint after ending pociredir development.
Strategic review underscores uncertainty: The engagement of Leerink Partners to explore mergers, acquisitions, or asset sales, with no assurance of any outcome, highlights elevated strategic and business uncertainty.

Insights

Fulcrum is sharply downsizing and exploring strategic transactions after ending its lead SCD program.

Fulcrum Therapeutics is implementing a deep restructuring, cutting its workforce from 57 to 9 employees and booking about $4.2 million in severance and related costs in Q2 2026. This indicates a significant scale-back of operations following the discontinuation of pociredir for sickle cell disease.

The company has engaged Leerink Partners LLC to evaluate strategic alternatives, including potential mergers, acquisitions, or asset or business sales. Whether any transaction occurs, and on what terms, remains uncertain based on the language that no outcome is assured.

Investors will likely focus on progress updates from this strategic review and any future disclosure of specific transaction proposals or outcomes in subsequent company communications or SEC submissions.

8-K Event Classification

2 items: 2.05, 8.01

2 items

Item 2.05 Costs Associated with Exit or Disposal Activities Financial

The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Restructuring charges: $4.2 million Workforce before restructuring: 57 full-time employees Workforce after restructuring: 9 full-time employees +4 more

7 metrics

Restructuring charges $4.2 million Expected aggregate charges for severance, benefits and related costs in Q2 2026

Workforce before restructuring 57 full-time employees Headcount prior to restructuring plan approval

Workforce after restructuring 9 full-time employees Target headcount after approximately 85% reduction

Workforce reduction percentage Approximately 85% Planned reduction in Fulcrum’s workforce under restructuring plan

Restructuring completion timing Q2 2026 Restructuring and related charges expected to be substantially completed

Board approval date May 31, 2026 Date Fulcrum’s board approved the restructuring plan

Workforce communication date June 4, 2026 Date Fulcrum communicated workforce reduction to employees

Key Terms

restructuring plan, workforce reduction, strategic alternatives, forward-looking statements, +2 more

6 terms

restructuring plan financial

"the board of directors of Fulcrum Therapeutics, Inc. approved a restructuring plan to significantly reduce Fulcrum’s operating expenses"

A restructuring plan is a company’s roadmap for reorganizing its operations, debts, or assets to improve financial health and efficiency; think of it as rewriting a household budget and chores when income changes. Investors care because the plan can affect a company’s ability to repay loans, generate profits, and sustain growth—successful restructuring can restore value, while a poorly executed one can signal continued trouble or reduced returns.

workforce reduction financial

"The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time employees"

strategic alternatives financial

"Fulcrum has initiated a comprehensive review of strategic alternatives intended to maximize stockholder value"

Strategic alternatives are different options a company considers to improve its value or achieve its goals, such as selling the business, merging with another company, or restructuring operations. For investors, understanding these options is important because they can significantly impact the company's future direction and its stock value, often signaling potential changes or opportunities.

forward-looking statements regulatory

"contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

sickle cell disease medical

"following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD"

Sickle cell disease is an inherited blood disorder where red blood cells become rigid and crescent-shaped, causing them to clump and block small blood vessels; this leads to recurrent pain, organ damage and higher risk of infection. For investors it matters because the condition drives ongoing healthcare costs, creates demand for new drugs, gene therapies and diagnostics, affects payer and hospital economics, and can influence workforce productivity and insurance liabilities—making progress or setbacks in treatments a market-moving factor.

severance financial

"aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs"

Severance is the payment and benefits an employer provides to an employee when their job ends, acting like a short-term financial safety net or final paycheck plus extras such as healthcare continuation or stock vesting. Investors care because severance obligations are real costs and potential liabilities that can reduce cash, affect reported profits, and signal how a company handles leadership changes or downsizing, which can influence future performance and shareholder value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/04/2026 - 04:05 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): May 31, 2026

    

Fulcrum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-38978	47-4839948
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

26 Landsdowne Street
Cambridge, Massachusetts		02139
(Address of principal executive offices)		(Zip Code)

     Registrant’s telephone number, including area code: (617) 651-8851

    

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	FULC	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05 Costs Associated with Exit or Disposal Activities.

On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD.

The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time employees, and is expected to be substantially completed during the second quarter of 2026.

Fulcrum expects to incur aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs. Fulcrum communicated the workforce reduction on June 4, 2026, and expects that substantially all of these charges will result in future cash expenditures and will be incurred during the second quarter of 2026.

The estimates described above are subject to a number of assumptions and actual results may differ materially from the estimates. Fulcrum may also incur additional charges or cash expenditures not currently contemplated due to events that may occur as the restructuring plan is implemented.

Item 8.01 Other Events.

As previously disclosed, Fulcrum has initiated a comprehensive review of strategic alternatives intended to maximize stockholder value.

In connection with this process, Fulcrum has engaged Leerink Partners LLC as its financial advisor to assist the Board of Directors in reviewing potential strategic alternatives, including, but not limited to, a merger, acquisition, business combination, sale or licensing of assets, or other strategic transaction involving the company or its assets.

Fulcrum has not set a timeline for the completion of this review and does not intend to provide further updates unless and until the Board of Directors has approved a course of action, the review process is concluded, or other disclosure is otherwise determined to be appropriate.

There can be no assurance that the strategic review process will result in any transaction or other strategic outcome. Fulcrum has not established a timetable for completion of this review and does not intend to provide further updates and until its Board of Directors has approved a course of action, the review process is concluded, or disclosure is otherwise determined to be appropriate.

Forward-Looking Statements

This current report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including express or implied statements regarding the effects of the discontinuation of pociredir in SCD; the effects and outcome of the strategic review and ability to maximize stockholder value; the restructuring plan and ability to reduce operating expenses and preserve capital; among others. All statements, other than statements of historical facts, contained in this current report are forward-looking statements, including express or implied statements regarding Fulcrum’s strategy, future operations, future financial position, prospects, plans and objectives of management. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrum’s decision to discontinue development of pociredir for SCD; the strategic review process, including identifying and executing one or more transactions that maximize stockholder value; implementing a restructuring and workforce reduction; as well as other more general risks associated with obtaining, maintaining or protecting intellectual property rights related to its product candidates and managing risks associated therewith; and managing expenses; among others. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Fulcrum’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in Fulcrum’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this current report on Form 8-K represent Fulcrum’s views as of the date hereof and should not be relied upon as representing Fulcrum’s views as of any date subsequent to the date hereof. Fulcrum anticipates that subsequent events and developments will cause Fulcrum’s views to change. However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			FULCRUM THERAPEUTICS, INC.

Date:	June 4, 2026	By:	/s/ Alex C. Sapir
			Name: Alex C. Sapir Title: President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What restructuring actions did Fulcrum Therapeutics (FULC) announce?

Fulcrum is implementing a major restructuring, cutting its workforce by about 85%, from 57 to 9 full-time employees. The plan aims to reduce operating expenses and preserve capital after discontinuing development of pociredir for sickle cell disease.

How much will Fulcrum Therapeutics (FULC) incur in restructuring charges?

Fulcrum expects about $4.2 million in restructuring charges, mainly for severance, employee benefits, and related costs. The company anticipates most of these charges will require future cash payments and be incurred during the second quarter of 2026.

When will Fulcrum’s workforce reduction be completed?

The workforce reduction from 57 to 9 employees is expected to be substantially completed during the second quarter of 2026. Fulcrum communicated the layoffs on June 4, 2026, and anticipates most related charges will be recorded in that same quarter.

What strategic alternatives is Fulcrum Therapeutics (FULC) considering?

Fulcrum is reviewing strategic alternatives such as a merger, acquisition, business combination, sale or licensing of assets, or other strategic transactions. Leerink Partners LLC has been engaged as financial advisor to assist the board in evaluating and potentially executing these options.

Is Fulcrum Therapeutics (FULC) committed to completing a transaction from its strategic review?

No, Fulcrum explicitly states there is no assurance the strategic review will result in any transaction or other outcome. The company has not set a timetable and plans further updates only if a course of action is approved or disclosure is otherwise appropriate.

Why is Fulcrum Therapeutics (FULC) restructuring and cutting staff?

The restructuring follows Fulcrum’s decision to discontinue development of pociredir for sickle cell disease. The board approved the plan to significantly reduce operating expenses and preserve capital while the company conducts a broader strategic review to seek ways to maximize stockholder value.

Filing Exhibits & Attachments

1 document